2021 Volume 80 Issue 5 Pages 253-257
The Novo-TTF 100A system is a novel antitumor treatment modality that demonstrated a survival effect forprimary glioblastoma in a multicenter open-label randomized phase III trial. We used this treatment modality for 3glioblastoma patients in Nihon University Itabashi Hospital. Here, we report the clinical courses of these 3 patients.Patient 1 was a 52-year-old male with left temporal glioblastoma who was treated via the Novo-TTF 100A systemfor 3 months. Patient 2 was a 62-year-old female with right thalamic glioblastoma who was treated via the NovoTTF 100A system for 13 months. Patient 3 was a 38-year-old male with left frontal glioblastoma who was treatedvia the Novo-TTF 100A system for 6 months. Patient 1 died 12 months after surgery, and Patient 2 died 18 monthsafter surgery. Patient 3 is being treated via the Novo-TTF 100A system. The details of the treatment course aredescribed in this article.
